Best Peptides for Recovery (2026): Evidence and Options

Which compounds are discussed for recovery & healing?

• ARA-290 (Cibinetide)

  Grade COverall compound grade

  Evidence scope: Small but real human trials, which is textbook C. An initial randomized double-blind pilot (n=22) in sarcoidosis small fiber neuropathy showed good tolerability and symptom improvement. A follow-up double-blind placebo-controlled RCT (n=38) found a significant increase in corneal nerve fiber density (about 14.5% up in the treatment group vs a decline in placebo), suggesting genuine nerve regeneration, and a later larger phase 2 (n=64) reinforced the corneal-nerve and pain signals. These are the first data showing a drug can regrow small nerve fibers, which is meaningful, but the trials are small, single-indication, and not confirmed in a pivotal phase 3. Not FDA-approved.

  Sources: ARA 290 improves symptoms and increases corneal nerve fiber density in sarcoidosis-associated small fiber neuropathy: randomized double-blind placebo-controlled trial, n=38 (Molecular Medicine, 2013)

  Cibinetide is a short peptide based on a region of erythropoietin (EPO). Crucially, it does NOT stimulate red blood cell production the way EPO does. Instead it activates the innate repair receptor, a heteroreceptor complex, which switches on anti-inflammatory and tissue-protective, tissue-regenerating signaling. In the neuropathy studies this shows up as actual regrowth of small nerve fibers. That separation of tissue repair from the blood-thickening effects of EPO is the whole point of the molecule.

  The most scientifically elegant peptide in this group: an EPO fragment engineered to keep the tissue-repair upside and drop the blood-clotting downside, with small human trials actually showing small nerve fibers regrowing. That is genuinely novel. But novel is not the same as proven, and the whole human record is a handful of small trials in one rare disease. Grade C. Worth watching for its neuropathy potential, not something to buy as a research chemical and inject based on a couple of pilot studies.

  See the evidence →

• BPC-157

  Grade DOverall compound grade

  Evidence scope: Grade D: only animal/preclinical evidence, no published human efficacy RCT (decision-tree rule 5 fired). The Sikirić rodent literature is extensive, but none of it has been replicated in a controlled human trial.

  Sources: FDA PCAC July 23-24, 2026 meeting (docket) · RAPS: FDA advisory committee backs controversial peptides (July 23, 2026 vote coverage) · Federal Register FDA-2025-N-6895 (April 2026 503A reclassification) · WADA Prohibited List (S0, banned at all times) · NCT07803250: first US drug-registered BPC-157 trial (University of Arkansas, rotator cuff repair). A registration, not a result: not yet recruiting, no results filed, and its own summary states BPC-157 has not yet been studied in formal human clinical trials.

  Promotes angiogenesis and tissue repair by upregulating growth-factor/VEGF and nitric-oxide pathways. Marketed as a "healing" peptide for gut, tendon and muscle injury, but that use is experimental.

  BPC-157 is not FDA-approved and is not yet legal to compound. On July 23, 2026 the FDA's PCAC panel voted 8 to 6 (1 abstention) to recommend adding it to the 503A list for ulcerative colitis, overriding the FDA's own scientists, but that is a recommendation only and the FDA has not decided. Human evidence stays Grade D: animal studies only. If you pursue it, wait for the FDA's ruling and use a licensed provider, never gray-market vials.

  See the evidence →

• KPV

  Grade DOverall compound grade

  Evidence scope: Grade D: preclinical only (cell and animal colitis models), no published human RCT (rule 5 fired).

  Sources: FDA PCAC July 23-24, 2026 meeting (docket) · RAPS: FDA advisory committee backs controversial peptides (July 23, 2026 vote coverage) · Federal Register FDA-2025-N-6895 (April 2026 503A reclassification)

  Anti-inflammatory tripeptide that suppresses NF-κB and pro-inflammatory signaling. Studied for gut and skin inflammation.

  KPV is not FDA-approved and is not yet legal to compound. On July 23, 2026 the FDA's PCAC panel voted 8 to 6 (1 abstention) to recommend adding it to the 503A list for wound healing and inflammatory conditions, overriding the FDA's own scientists, but the FDA still decides and has not acted. Human evidence stays Grade D: cell and animal anti-inflammatory data only, no human trials.

  See the evidence →

• MGF (Mechano Growth Factor)

  Grade DOverall compound grade

  Evidence scope: Evidence is preclinical only. The optimistic case rests on cell-culture and animal work suggesting the MGF-E peptide can activate satellite cells. But a well-controlled 2014 in-vitro study explicitly designed to test it found the peptide had no effect on myoblast or muscle-stem-cell proliferation at concentrations up to 500 ng/ml, and a 2012 review concluded its efficacy in humans is unproven. There are no human trials showing MGF injections build muscle. Grade D reflects animal/in-vitro-only evidence with a notable negative result.

  Sources: Fornaro M, et al. MGF peptide has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab, 2014 (PMID 24253050). · Zablocka B, et al. Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? Front Endocrinol, 2012.

  MGF is the C-terminal E-domain of the IGF-1Ec splice variant, produced locally in skeletal muscle in response to mechanical overload or damage. The proposed mechanism is autocrine/paracrine activation of muscle satellite cells (the resident stem cells that repair and enlarge fibers), acting through a receptor distinct from the classic IGF-1 receptor. In practice the receptor and downstream signaling remain poorly characterized, and whether the synthetic peptide reproduces the biology of the natural splice event is unresolved.

  Skip it. The idea (a local muscle-repair growth factor you can inject) is attractive, but the honest read of the literature is preclinical at best and negative in the one rigorous cell study. There is no human evidence it builds muscle, it is banned in sport, and injecting an unverified growth factor is not a low-risk bet.

  See the evidence →

• MK-677 (Ibutamoren)

  Grade COverall compound grade

  Evidence scope: MK-677 has real, multi-study human RCT data, well beyond anything the GHRPs have: a 2-year double-blind trial in older adults (Nass 2008) and randomized bone-turnover trials (Murphy 1999). It reliably raises GH and IGF-1 into a youthful range and modestly increases fat-free mass. But it is not FDA-approved, the 2-year trial showed no improvement in strength or function despite the lean-mass gain, and it measurably reduced insulin sensitivity and raised fasting glucose. Real human efficacy on a surrogate (FFM, IGF-1) but no approval and a meaningful metabolic downside puts it at C, the top of this group.

  Sources: Nass 2008, Ann Intern Med, 2-year RCT of oral MK-677 in healthy older adults: increased fat-free mass and IGF-1 to youthful range, but raised fasting glucose and reduced insulin sensitivity · Murphy 1999, J Bone Miner Res, oral MK-677 increased markers of bone turnover in 187 elderly adults (randomized, placebo-controlled) · WADA Prohibited List, growth hormone secretagogues incl. ibutamoren (MK-677) banned at all times (S2.2.4)

  Non-peptide agonist of the ghrelin receptor (GHS-R1a) that mimics ghrelin to drive sustained, roughly physiological increases in growth hormone and IGF-1. Because it is orally bioavailable and long-acting, one daily dose keeps GH/IGF-1 elevated, unlike the injectable peptide GHRPs. That same sustained GH/IGF-1 elevation is what drives its main downside: reduced insulin sensitivity and higher fasting glucose.

  The most-studied and only orally-active option in this group, with genuine 2-year human RCT data behind it, which is why it grades C and not D. But the same trial that proves it works also shows the catch: modest lean-mass gain, no functional benefit, and worse insulin sensitivity. Not FDA-approved, research-only, and a poor idea for anyone with blood-sugar concerns.

  See the evidence →

• PEG-MGF (Pegylated Mechano Growth Factor)

  Grade DOverall compound grade

  Evidence scope: Evidence is animal and in-vitro only. Rodent muscle-injury models report increased satellite cell number and cross-sectional area with PEG-MGF, and the PEGylation rationale (extended half-life) is chemically sound. But there are no controlled human trials, and the parent peptide MGF failed to show activity in a rigorous cell study. Grade D reflects preclinical-only evidence with no human efficacy data.

  Sources: Fornaro M, et al. MGF peptide has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab, 2014 (PMID 24253050). · Zablocka B, et al. Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? Front Endocrinol, 2012.

  PEG-MGF is the MGF (IGF-1Ec E-domain) peptide conjugated to polyethylene glycol. Native MGF has a very short systemic half-life (minutes); PEGylation slows clearance and is meant to give the peptide time to reach tissue and act on satellite cells. The proposed downstream biology is identical to MGF: satellite cell activation, proliferation, and fusion to support fiber repair and hypertrophy. Whether extending the half-life of a peptide that may not be active in the first place produces a real anabolic effect is exactly the open question.

  Skip it. PEG-MGF is a chemically reasonable attempt to fix MGF's short half-life, but fixing the delivery of a compound with no proven human effect does not create a proven human effect. Animal data only, banned in sport, unverified injectable. Not worth the risk.

  See the evidence →

• Sermorelin

  Grade BOverall compound grade

  Evidence scope: Grade B: previously FDA-approved (Geref) with human data for its approved indications, and still widely compounded (rule 3 fired: prior FDA approval backed by human trials). Withdrawn ~2008 for business reasons, not safety.

  Sources: FDA 503A bulks list (fda.gov/media/94155/download) · Drugs@FDA: Geref (sermorelin) approval history · WADA Prohibited List (S2, GHRH analog)

  Stimulates natural pituitary growth-hormone release as the shortest active GHRH(1-29) fragment. The "gentler," physiologic GH-axis peptide.

  Sermorelin is legally compoundable (503A) thanks to its prior FDA approval as Geref. Human evidence is Grade B: real historical trial data. It is the best-evidenced GH-axis peptide with a legal supervised route today.

  See the evidence →

• SS-31 (Elamipretide)

  Grade COverall compound grade

  Evidence scope: There is genuine human trial data, which is more than most peptides here can claim, but the results are mixed. The pivotal Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy (218 patients) missed both primary endpoints: the 6-minute walk test difference was -3.2 m (p=0.69) and the fatigue score difference was -0.07 (p=0.37). Separately, the dry-AMD program produced a positive Phase 2 ellipsoid-zone signal that was strong enough to carry a regulatory-accepted endpoint into the ongoing Phase 3 ReNEW study. So: a failed flagship indication alongside a live, better-looking one. Grade C reflects human trials of genuinely mixed results, not a clean win. It is not yet approved for anything.

  Sources: Karaa A, et al. Efficacy and Safety of Elamipretide in Primary Mitochondrial Myopathy: MMPOWER-3 Randomized Clinical Trial. Neurology, 2023;101(3):e238-e252. · ReNEW: Phase 3 Study of Subcutaneous Elamipretide in Dry Age-Related Macular Degeneration (ongoing). · Genotype-specific effects of elamipretide in primary mitochondrial myopathy: post hoc analysis of MMPOWER-3. Orphanet J Rare Dis, 2024.

  Elamipretide is a small cell-permeable tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that concentrates in the inner mitochondrial membrane and binds cardiolipin. By stabilizing cardiolipin and the associated respiratory-chain supercomplexes, it is proposed to improve electron transport efficiency, reduce reactive oxygen species, and restore ATP production in mitochondria that are dysfunctional. Because mitochondrial dysfunction sits underneath many age-related and rare diseases, it has been tested across mitochondrial myopathy, heart failure, and dry age-related macular degeneration.

  The most legitimate science on this list, and still not a green light. Elamipretide is a real drug candidate with a plausible mitochondrial mechanism and clean tolerability, but its flagship mitochondrial-myopathy Phase 3 missed its endpoints. The dry-AMD program is the one to watch. Until a Phase 3 reads out positive and it earns approval, treat grey-market SS-31 as an unproven, unapproved injectable and keep expectations low.

  See the evidence →

• TB-500

  Grade DOverall compound grade

  Evidence scope: Grade D: animal/preclinical only for the TB-500 fragment, no human RCT (rule 5 fired). Note: full-length Thymosin β-4 reached human Phase 2 via RegeneRx, but that is a different molecule from the TB-500 fragment sold to consumers.

  Sources: FDA PCAC July 23-24, 2026 meeting (docket) · RAPS: FDA advisory committee backs controversial peptides (July 23, 2026 vote coverage) · Federal Register FDA-2025-N-6895 (April 2026 503A reclassification) · WADA Prohibited List (S2, growth factors, Tβ4 explicitly named)

  Regulates actin and promotes cell migration, angiogenesis and wound healing. Marketed for soft-tissue and tendon recovery.

  TB-500 is not FDA-approved and is not yet legal to compound. On July 23, 2026 the FDA's PCAC panel voted 8 to 6 (1 abstention) to recommend adding it to the 503A list for wound healing, overriding the FDA's own scientists, but the FDA still decides and has not acted. Human evidence stays Grade D: the fragment sold to consumers has animal data only. The full-length Tβ4 human trials are a different molecule.

  See the evidence →

• Thymosin Beta-4

  Grade BOverall compound grade

  Evidence scope: Higher than pure preclinical because thymosin beta-4 has actually run positive human randomized trials, but only as an eye drop. A phase 2 RCT in severe dry eye hit significant endpoints (35% less ocular discomfort, 59% less corneal staining vs vehicle), and a phase 3 RCT in neurotrophic keratopathy showed strong healing (6/10 vs 1/8 healed, significant by day 43). A first-in-human phase 1 confirmed injectable recombinant Tbeta4 was well tolerated. That said: it is not FDA-approved (the phase 3 SEER-3 ocular program later missed its primary endpoint), cardiac and systemic-healing claims rest on animal models, and the injected TB-500 that people actually buy has almost no human efficacy data. So B for the molecule on its ophthalmic trials, with the honest caveat that the injectable use is far less supported.

  Sources: Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial (Cornea, 2015) · 0.1% RGN-259 (thymosin beta4) for neurotrophic keratopathy: randomized, placebo-controlled, double-masked phase 3 trial (Int J Mol Sci, 2022) · First-in-human phase 1 study of recombinant human thymosin beta4 in healthy volunteers (J Cell Mol Med, 2021)

  The main job of thymosin beta-4 is to bind and sequester G-actin, the building-block protein of the cell skeleton. By managing the actin pool it drives cell migration, which is central to wound healing. It also promotes new blood vessel growth (angiogenesis), tamps down inflammatory signaling, and can reduce cell death after injury. TB-500 is a widely sold fragment marketed as a related actin-binding peptide. These mechanisms explain the interest in healing, cardiac repair, and the cornea.

  Two different stories share one molecule. As an eye drop (RGN-259) it has legitimate positive human trials and grades a B. As the injectable TB-500 that the recovery crowd actually buys, human efficacy data is basically absent, and you are extrapolating from animal healing studies. It is not FDA-approved in any form. If you are drawn to it for tendon or muscle recovery, be clear-eyed that you are self-experimenting with an unapproved, WADA-banned peptide whose human evidence lives in ophthalmology, not sports medicine.

  See the evidence →